60 Degrees Pharmaceuticals develops and commercializes medicines for vector-borne disease, led by ARAKODA® (tafenoquine), an FDA-approved malaria prevention drug for adults. Company news commonly covers ARAKODA access and marketing channels for U.S. travelers, including telehealth and prescription-savings arrangements, as well as financial results and capital-market actions tied to its Nasdaq-listed common stock and warrants.
Updates also address tafenoquine development beyond malaria prophylaxis, including reports from studies in relapsing babesiosis, and work involving Australian Chestnut Extract, castanospermine and celgosivir-related research for non-prescription or infectious-disease applications. The company’s announcements frequently combine product availability, regulatory interactions, license arrangements, clinical data and corporate-structure matters such as reverse stock split actions.
60 Degrees Pharmaceuticals (SXTP) plans to end enrollment in its severe babesiosis trial at 30 patients and report results in January 2027. The blinded, randomized trial compares tafenoquine plus standard care with placebo plus standard care. Following its October 1 interim review, the independent safety monitoring board recommended completing the planned enrollment of 33 patients; no safety issues were identified. The company gives limited added statistical power and a potential delay until fall 2027 as reasons for stopping enrollment. Endpoint results remain undetermined.
Separately, molecular cure was confirmed in the first three expanded-access patients receiving tafenoquine with atovaquone-containing regimens for relapsing, treatment-refractory babesiosis. Final screening data from two more patients are expected in early November 2026. The company plans to request an FDA meeting in January 2027 about a supplemental approval application and a possible accelerated approval pathway.
60 Degrees Pharmaceuticals (SXTP) will release interim results from its hospitalized babesiosis study and host an investor webinar on October 6, 2026.
The study, NCT06207370, evaluates tafenoquine in patients hospitalized with severe babesiosis. The webinar begins at 11:00 a.m. ET and features Dr. Peter Krause and Dr. Edouard Vannier. It will review clinical data from the company's hospital and expanded access studies, alongside published literature, and discuss tafenoquine's potential role in recurrent tick-borne infections. A live question-and-answer session will follow. Tafenoquine is approved in the United States for malaria prevention as ARAKODA, but not for treating or preventing babesiosis.
60 Degrees Pharmaceuticals (SXTP) will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.
An on-demand, pre-recorded company presentation focused on its vector-borne disease programs will be available to registered attendees and the public starting Friday, September 11, 2026, at 7:00 a.m. ET via the conference portal. Management will also hold one-on-one meetings with institutional investors and other participants during the event.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported second quarter 2026 results for the period ended June 30, 2026. Net product revenues were approximately $208 thousand, up about 106% from approximately $101 thousand in the second quarter of 2025. Gross profit on product revenues was approximately $57 thousand, compared with about $51 thousand a year earlier.
Operating expenses were approximately $2.33 million, up from about $1.86 million in the prior-year quarter. Net loss attributable to common stockholders was approximately $2.40 million, or $0.90 per share, versus a net loss of about $1.84 million, or $5.01 per share, in the second quarter of 2025.
The company develops medicines for vector-borne diseases and markets ARAKODA (tafenoquine) for malaria prevention, with three active clinical trials underway for babesiosis.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) entered into definitive agreements for a private placement of 574,713 shares of common stock (or pre-funded warrants in lieu) plus series A and short-term series B warrants to purchase up to 574,713 shares each, at a purchase price of $1.74 per share and accompanying warrants, priced at-the-market under Nasdaq rules.
The series A and B warrants have an exercise price of $1.49 per share, are exercisable upon issuance, with series A expiring five years and series B twenty-four months from the effective date of a resale registration statement. Closing is expected on or about July 31, 2026, subject to customary conditions. Gross proceeds are expected to be approximately $1.0 million before fees and expenses, excluding any warrant exercise proceeds. The securities are being offered in a private placement under Section 4(a)(2) and/or Regulation D, and the company intends to use net proceeds for working capital and general corporate purposes.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) reported that it has enrolled the minimum 24 hospitalized patients required to trigger an interim analysis in its double-blind, randomized, placebo-controlled Phase 2/3 trial of oral tafenoquine plus standard of care for severe babesiosis (NCT06207370). The data safety and monitoring board will analyze the primary endpoint of time to sustained clinical recovery and the key secondary endpoint of time to molecular clearance of Babesia parasites, with topline interim results expected by October 6, 2026.
Depending on statistical significance, the board may recommend early study halt, additional enrollment, or study closure. Enrollment will continue during this period. Following the interim analysis, 60 Degrees plans to request an FDA meeting to discuss the regulatory pathway for a potential supplemental NDA for tafenoquine in babesiosis. Tafenoquine (marketed as ARAKODA for malaria prophylaxis) is not currently approved for treating or preventing babesiosis, and no FDA-approved therapies exist for this disease.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) signed an exclusive option agreement with the Florida State University Research Foundation covering IP for therapeutic development of castanospermine in Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease.
The deal includes a U.S. license option and time to design a commercialization and development strategy, aligning with the company’s vector-borne disease focus and complementing tafenoquine work for babesiosis. Castanospermine has shown broad antiviral and immunomodulatory activity in preclinical studies and has substantial human safety experience via celgosivir trials. The company is re-evaluating its dietary supplement regulatory strategy after FDA discussions, while prioritizing prescription drug development pathways for castanospermine.
60 Degrees Pharma (NASDAQ:SXTP) reported that an independent Data Safety Monitoring Board found no safety concerns in the first six patients in its Phase 2 B-Free chronic babesiosis study and recommended trial continuation.
The study tests an ARAKODA® tafenoquine regimen for severe persistent fatigue; tafenoquine is only FDA-approved for malaria prophylaxis.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) signed an exclusive patent license with Florida State University to enable large-scale extraction and purification of castanospermine from Castanospermum australe seeds for non-prescription uses.
The FDA issued a Non-Notification Letter on the company’s New Dietary Ingredient Notification for Australian Chestnut Extract; a meeting is set for July 1, 2026, to clarify required safety information before a revised filing.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) reported early enrollment of the first 2026 tick-season patient in its randomized, double-blind, placebo-controlled trial of tafenoquine for hospitalized babesiosis. Enrollment is about one month ahead of schedule, with at least 24 patients targeted before an interim analysis.
The study at five Northeastern U.S. sites has two main endpoints: clinical symptom resolution and parasite clearance, each with separate interim analyses. Minimum enrollment for interim review could be reached by early July 2026. Tafenoquine is FDA-approved for malaria prophylaxis but not for babesiosis.